Alvotech ALVO
We take great care to ensure that the data presented and summarized in this overview for Alvotech is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALVO
View all-
Vanguard Group Inc Valley Forge, PA3.16MShares$41 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$35.1 Million47.01% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca2.53MShares$32.9 Million0.61% of portfolio
-
Littlejohn & CO LLC1.32MShares$17.1 Million6.78% of portfolio
-
Legal & General Group PLC London, X01MShares$13 Million0.0% of portfolio
-
Sculptor Capital LP New York, NY945KShares$12.3 Million0.42% of portfolio
-
Balyasny Asset Management LLC Chicago, IL848KShares$11 Million0.02% of portfolio
-
Point State Capital LP New York, NY730KShares$9.48 Million0.23% of portfolio
-
Lodbrok Capital LLP London, X0716KShares$9.3 Million1.98% of portfolio
-
Geode Capital Management, LLC Boston, MA188KShares$2.45 Million0.0% of portfolio
Latest Institutional Activity in ALVO
Top Purchases
Top Sells
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Insider Transactions at ALVO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|